Sigyn Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 13, 2021 at 03:18 am IST
Share
Sigyn Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 0.665904 million compared to USD 0.29599 million a year ago. Basic loss per share from continuing operations was USD 0.02. Diluted loss per share from continuing operations was USD 0.02.
For the nine months, net loss was USD 1.78 million compared to USD 0.807568 million a year ago. Basic loss per share from continuing operations was USD 0.05. Diluted loss per share from continuing operations was USD 0.05.
Sigyn Therapeutics, Inc. is a development-stage company. The Company is focused on creating therapeutic solutions that address unmet needs in global health. The Company's product candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Its treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines. The Company's development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis.
SIGN THERPAR 
